Overview

1. 1
   Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.

   Cell · 2022

   WLWenjie LuoSGShiaoching GongGMGiovanni ManfrediLGLi Gan

   PMID: 35063084·PMCID: PMC8857049·DOI·Senior author·285 citations·Abstract
2. 2
   Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resilience.

   Nature neuroscience · 2023

   LFLi FanRKRavi Kumar NagiriSGShiaoching GongWLWenjie Luo+3 more →LGLi Gan

   PMID: 37095396·PMCID: PMC10166855·DOI·Senior author·252 citations·Abstract
3. 3
   Human iPSC 4R tauopathy model uncovers modifiers of tau propagation.

   Cell · 2024

   YWYuansong WanAEAlessandro EvangelistiLFLi FanMSManu Sharma+3 more →LGLi Gan

   PMID: 38582079·PMCID: PMC11365117·DOI·Senior author·64 citations·Abstract

• Sub-PI

  Mechanisms and intervention of cGAS signaling in brain trauma-induced neuroinflammation and neurodegeneration

  National Institute of Neurological Disorders and Stroke · 2025–2030 · via University of Maryland, Baltimore

  Abstract & 2 publications

  R01NS145443-02
• MPI

  CH25H mediates microglial neuroinflammation and tau toxicities in AD

  National Institute on Aging · 2025–2030

  Abstract & 1 publication

  R01AG096902-01
• PI

  Mapping proteomic changes of tauopathy in human neurons

  National Institute on Aging · 2025–2030

  Abstract & 3 publications

  R01AG092462-02
• KP

  Investigating the role of progranulin microglial replacement therapy in Parkinson's Disease

  National Institute of Neurological Disorders and Stroke · 2026–2028Career

  Abstract

  K99NS149066-01
• Sub-PI

  The Alzheimer's Disease Tau Platform Clinical Trial

  National Institute on Aging · 2023–2028 · via University of California, San Francisco

  Abstract & 1 publication

  R01AG078457-02
• KP

  Investigating Modifiers of Human Microglia-Neuron Interplay in Tau Propagation In Vivo

  National Institute on Aging · 2026–2028Career

  Abstract

  K99AG095211-01A1
• PI

  Validating STING as a therapeutic target for Parkinson disease using human iPSC models (MJFF-028881) to 2026 RFA: T2T Neuroinflammation Target Validation

  Michael J. Fox Foundation for Parkinson's Research · 2026–2028

  MJFF-028881
• PI

  Human CGAS inhibitors to treat neurodegeneration in Alzheimer's disease

  NIA · 2026–2028 · via NIH RePORTER

  Abstract

  R44AG099654-01
• Sub-PI

  Study of Selective Cell and System Vulnerability in Alzheimer's Disease

  National Institute on Aging · 2023–2028 · via University of North Carolina at Chapel Hill

  Abstract & 10 publications

  R01AG079291-04
• PI

  Microglial-astrocytic mechanisms of APOE3 Christchurch-mediated resilience to tauopathy

  Cure Alzheimer’s Fund · 2025–2027

  CAF 255893-01
• PI

  Targeting maladaptive innate immune response to treat PD

  JPB Foundation, The · 2024–2027

  JBP 2024-4710
• PI

  Systematic Identification of Biomarkers to Distinguish FTD-Tau from TDP-43

  Rainwater Charitable Foundation · 2026–2027

  RCF 261005-01
• Sub-PI

  Studying NeuroHIV and addictive substances in a human microglia-neuron chimera mouse model

  National Institute on Drug Abuse · 2025–2027 · via The J. David Gladstone Institutes

  Abstract

  R61DA065570-02
• Sub-PI

  Elucidate the Roles of Alzheimer's Disease Variants in Gene Expression and AD Phenotypes

  National Institute on Aging · 2022–2027 · via The Regents of the University of California, San Francisco

  Abstract & 8 publications

  RF1AG079557-02
• Co-I

  A calvarial stem cell mediating a new bone-brain axis in Alzheimer's disease

  National Institute on Aging · 2025–2027Career

  Abstract

  K99AG090732-01
• PI

  RCA with Arvinas, Inc

  Arvinas, Inc. · 2026–2027BioPharma Alliance

  BP 262896-01
• MPI

  cGAS inhibitors for Alzheimer's disease treatment

  National Institute on Aging · 2021–2027

  Abstract & 23 publications

  R01AG074541-05
• Sub-PI

  Hevolution Network on Senescense in Aging

  Hevolution Foundation · 2024–2027 · via Yeshiva University

  AECM 232620-03
• Co-I

  TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer's Disease

  National Institute on Aging · 2022–2027 · via Cleveland Clinic Lerner College of Medicine

  Abstract & 7 publications

  R01AG076448-01
• Sub-PI

  Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers

  National Institute on Aging · 2022–2027 · via Cornell University - Ithaca

  Abstract & 4 publications

  R01AG077899-05
• Sub-PI

  Development of novel genomic approaches for profiling cellular temporal-spatial dynamics of neurogenesis in Aging and Alzheimer's disease

  National Institute on Aging · 2022–2027 · via Rockefeller University

  Abstract & 1 publication

  R01AG076932-05
• PI

  Sex-biased TLR7 signaling in demyelination and its inhibition by small molecules

  Cure Alzheimer’s Fund · 2025–2026

  CAF 245217-01
• PI

  Genome-scale perturb-seq of human neurons and astrocytes in vivo

  Chan Zuckerberg Initiative · 2025–2026

  CZI 253116-01
• KP

  Modeling pathological Tau propagation in human brain cells in vivo

  BrightFocus Foundation · 2024–2026

  A2024003F
• PI

  Methods to optimize the human cGAS inhibitor leads

  Rainwater Charitable Foundation · 2025–2026

  RCF 250950-01
• PI

  Decoding the molecular mechanisms underlying the copathologies in PSP

  Rainwater Charitable Foundation · 2025–2026

  RCF 251050-01
• Sub-PI

  Acetylated Tau Immunotherapy for Alzheimer's Disease

  National Institute on Aging · 2024–2026 · via Aeton Therapeutics Inc.

  Abstract

  R41AG085770-01
• PI

  Evaluation of a novel human cGAS inhibitor using human iPSC derived models

  Harrington Discovery Institute, The · 2024–2026

  HDIT 235842-01
• Co-I

  Structure and Function of Tau

  National Institute on Aging · 2020–2026

  Abstract

  RF1AG066493-01A1
• PI

  Dissecting immune resilience mechanism in human neuron-microglia chimera model

  Carol and Gene Ludwig Family Foundation · 2024–2026

  No publications yet

  CGLFF 242405-02
• PI

  Biopharma Agreement with NeuroVanda Therapeutics

  Neurovanda Therapeutics Pte. LTD · 2025–2026BioPharma Alliance

  BP 255354-01
• Co-I

  Elucidating the Cell-Type Specific Neuroprotective Mechanisms in the APOE3 Christchurch Mutation in Alzheimer's Disease

  National Institute on Aging · 2023–2026Fellowship

  Abstract & 2 publications

  F32AG085960-01
• PI

  Maladaptive Antiviral Pathways In Alzheimer'S Disease

  National Institute on Aging · 2021–2026

  Abstract & 30 publications

  R01AG072758-05

• hTREM2-CV Mouse
• hTREM2-R47H Mouse

  PMID 34851693
• Human APOE3 WT KI Mouse
• Inhibition of the UFMylation Cascade for Treatment of Alzheimer's Disease and 4R Tauopathies

  Provisional filedPoC Data·PMID 38582079·Overview

  10763

• Protein Secreted by Immune Cells May Help Drive Brain Aging

  August 11, 2026

  Brain-resident immune cells that have reached an old-age state called senescence secrete a protein that causes dysfunction in other brain cells, according to a study led by investigators at Weill Cornell Medicine.

• Inflammation May Drive Dravet Syndrome, Offering a Potential New Treatment Target

  July 29, 2026

  An overactive immune response in the brain may play a role in Dravet Syndrome, a rare and severe genetic epilepsy that typically begins in infancy, according to Weill Cornell Medicine researchers.

• Research Shifts Toward Shared Mechanisms in Neurodegenerative Diseases

  April 3, 2026

  Leaders in the field discussed a shift in research toward looking at shared mechanisms in neurodegenerative diseases at the recent 13th annual Helen and Robert Appel Alzheimer’s Disease Research Institute Symposium held in the Belfer Research Building at Weill Cornell Medicine.

• Alzheimer’s Protective Mutation Works by Taming Inflammation in the Brain

  June 23, 2025

  A rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine.

• Looking Beyond Beta-Amyloid: New Paths in Alzheimer's Research

  June 3, 2025

  At the 12th annual Helen and Robert Appel Alzheimer’s Disease Research Institute Symposium, scientists and clinicians shared their latest research which is advancing how Alzheimer’s disease is diagnosed and treated.

• Senescent Microglia Release Protein That Disrupts Myelin, Riles Neurons

  Alzforum · August 20, 2026